Posters

  1. Small Molecule Screen Identifies Targets That Increase AAV9 Production In Suspension HEK293 Cells 1/29/2025

    We developed ATLAS, a high-throughput screening platform that enhances AAV9 production by identifying key biological targets—unlocking new opportunities to improve gene therapy manufacturing efficiency.

  2. Development And Scalability Of A Robust Suspension-Based Production Process For AAV9 1/29/2025

    Our scalable suspension-based production process for AAV9, proven across multiple serotypes, offers a robust platform for efficient, high-quality gene therapy manufacturing.

  3. Gain And Loss-Of-Function Screens Identify Targets That Ramp Up AAV Production 1/29/2025

    Enhance rAAV production efficiency and reduce costs with our innovative approaches, including small molecule modulation and engineered HEK293 cell lines, now being validated for scalability and quality.

  4. Successful Scale-Up Validation Of A Small-Molecule Compound For Increased AAV Yields 1/29/2025

    Here, we present validation data from controlled bioreactor studies, demonstrating the scalability of SM-016 using the Ambr® 15 bioreactor system.

  5. A Differentiated End-To-End Process Suspension-Based Platform For The Manufacturing Of AAVs 1/29/2025

    Accelerate your AAV gene therapy development with our scalable, high-quality suspension platform, designed to streamline manufacturing, reduce costs, and meet evolving regulatory standards.

  6. Exploring Genetic Profiles Of rAAVs Through Orthogonal DNA Profiling Methods 1/29/2025

    This study focuses on analyzing encapsidated DNA size distribution and kanamycin resistance gene (Kan) impurities using alkaline gel electrophoresis, ddPCR, and NGS.

  7. Rapid AAV Pre-Formulation Screening Using A Buffer Kit, Minimal Sample Requirement 1/29/2025

    Optimize AAV vector stability and streamline development with our rapid, high-throughput pre-formulation screening approach using minimal sample requirements.

  8. Whole Genome High-Throughput Screen Identified microRNAs Enhancing rAAV Production 1/29/2025

    Leveraging our optimized Ascend HEK293 suspension platform and genome-wide microRNA screening, we invite collaboration to advance rAAV production efficiency and meet the growing demand for high-quality gene therapy vectors.

  9. A Genome-Wide High-Throughput Gain-Of-Function Screen Identifies Novel Targets For Improved AAV9 Production 1/13/2025

    Overcoming manufacturing challenges in AAV production is essential to improving quality, reducing costs, and ensuring safer, more accessible gene therapies for patients worldwide.

  10. Manufacturing Of A Broad Range Of AAV Capsids Using Our Suspension Platform 1/13/2025

    Yield and quality metrics vary significantly between AAV capsids, emphasizing the need for a modular manufacturing platform to address their unique requirements.